These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 15464063

  • 41. Putative physiological significance of vasopressin V1a receptor activation in rat pituicytes.
    Rosso L, Peteri-Brunbäck B, Mienville JM.
    J Neuroendocrinol; 2004 Apr; 16(4):313-8. PubMed ID: 15089968
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Body water balance and body temperature in vasopressin V1b receptor knockout mice.
    Daikoku R, Kunitake T, Kato K, Tanoue A, Tsujimoto G, Kannan H.
    Auton Neurosci; 2007 Oct 30; 136(1-2):58-62. PubMed ID: 17512263
    [Abstract] [Full Text] [Related]

  • 45. Small-molecule vasopressin-2 receptor antagonist identified by a g-protein coupled receptor "pathway" screen.
    Yangthara B, Mills A, Chatsudthipong V, Tradtrantip L, Verkman AS.
    Mol Pharmacol; 2007 Jul 30; 72(1):86-94. PubMed ID: 17435162
    [Abstract] [Full Text] [Related]

  • 46. The effect of vasopressin and related compounds at V1a and V2 receptors in animal models relevant to human disease.
    Petersen MB.
    Basic Clin Pharmacol Toxicol; 2006 Aug 30; 99(2):96-103. PubMed ID: 16918709
    [Abstract] [Full Text] [Related]

  • 47. Vasopressin and angiotensin receptors of the medial septal area of the brain in the control of thirst and salt appetite induced by vasopressin in water-deprived and sodium-depleted rats.
    Maria Pavan de Arruda Camargo G, Antônio de Arruda Camargo L, Saad WA.
    Pharmacol Biochem Behav; 2007 Oct 30; 87(4):393-9. PubMed ID: 17573101
    [Abstract] [Full Text] [Related]

  • 48. New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists.
    Yea CM, Allan CE, Ashworth DM, Barnett J, Baxter AJ, Broadbridge JD, Franklin RJ, Hampton SL, Hudson P, Horton JA, Jenkins PD, Penson AM, Pitt GR, Rivière P, Robson PA, Rooker DP, Semple G, Sheppard A, Haigh RM, Roe MB.
    J Med Chem; 2008 Dec 25; 51(24):8124-34. PubMed ID: 19053774
    [Abstract] [Full Text] [Related]

  • 49. Overview of cellular electrophysiological actions of vasopressin.
    Raggenbass M.
    Eur J Pharmacol; 2008 Apr 07; 583(2-3):243-54. PubMed ID: 18280467
    [Abstract] [Full Text] [Related]

  • 50. Design and synthesis of potent, highly selective vasopressin hypotensive agonists.
    Stoev S, Cheng LL, Manning M, Wo NC, Szeto HH.
    J Pept Sci; 2006 Sep 07; 12(9):592-604. PubMed ID: 16625682
    [Abstract] [Full Text] [Related]

  • 51. Involvement of vasopressin in affective disorders.
    Surget A, Belzung C.
    Eur J Pharmacol; 2008 Apr 07; 583(2-3):340-9. PubMed ID: 18255056
    [Abstract] [Full Text] [Related]

  • 52. Effects of novel vasopressin receptor antagonists on renal function and cardiac hypertrophy in rats with experimental congestive heart failure.
    Bishara B, Shiekh H, Karram T, Rubinstein I, Azzam ZS, Abu-Saleh N, Nitecki S, Winaver J, Hoffman A, Abassi ZA.
    J Pharmacol Exp Ther; 2008 Aug 07; 326(2):414-22. PubMed ID: 18467593
    [Abstract] [Full Text] [Related]

  • 53. In vitro and in vivo pharmacological characterization of PF-01354082, a novel partial agonist selective for the 5-HT(4) receptor.
    Mikami T, Komada T, Sugimoto H, Suzuki K, Ohmi T, Kimura N, Naganeo R, Nakata E, Nakatani K, Toga T, Eda H, Sakakibara M.
    Eur J Pharmacol; 2009 May 01; 609(1-3):5-12. PubMed ID: 19285067
    [Abstract] [Full Text] [Related]

  • 54. Muscarinic subtype affinity and functional activity profile of 1-methyl-2-(2-methyl-1,3-dioxolan-4-yl)pyrrolidine and 1-methyl-2-(2-methyl-1,3-oxathiolan-5-yl)pyrrolidine derivatives.
    Dei S, Angeli P, Bellucci C, Buccioni M, Gualtieri F, Marucci G, Manetti D, Matucci R, Romanelli MN, Scapecchi S, Teodori E.
    Biochem Pharmacol; 2005 Jun 01; 69(11):1637-45. PubMed ID: 15896343
    [Abstract] [Full Text] [Related]

  • 55. Next-generation spirobenzazepines: identification of RWJ-676070 as a balanced vasopressin V1a/V2 receptor antagonist for human clinical studies.
    Xiang MA, Rybczynski PJ, Patel M, Chen RH, McComsey DF, Zhang HC, Gunnet JW, Look R, Wang Y, Minor LK, Zhong HM, Villani FJ, Demarest KT, Damiano BP, Maryanoff BE.
    Bioorg Med Chem Lett; 2007 Dec 01; 17(23):6623-8. PubMed ID: 17942308
    [Abstract] [Full Text] [Related]

  • 56. The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonists.
    Napier S, Wishart G, Arbuckle W, Baker J, Barn D, Bingham M, Brown A, Byford A, Claxton C, Craighead M, Buchanan K, Fielding L, Gibson L, Goodwin R, Goutcher S, Irving N, MacSweeney C, Milne R, Mort C, Presland J, Sloan H, Thomson F, Turnbull Z, Young T.
    Bioorg Med Chem Lett; 2011 May 15; 21(10):3163-7. PubMed ID: 21458261
    [Abstract] [Full Text] [Related]

  • 57. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.
    Manning M, Cheng LL, Stoev S, Wo NC, Chan WY, Szeto HH, Durroux T, Mouillac B, Barberis C.
    J Pept Sci; 2005 Oct 15; 11(10):593-608. PubMed ID: 15880385
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Blockade of the V(1b) receptor reduces ACTH, but not corticosterone secretion induced by stress without affecting basal hypothalamic-pituitary-adrenal axis activity.
    Spiga F, Harrison LR, Wood S, Knight DM, MacSweeney CP, Thomson F, Craighead M, Lightman SL.
    J Endocrinol; 2009 Mar 15; 200(3):273-83. PubMed ID: 19008333
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.